Christopher Kenney
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christopher Kenney
The proxy statement of Xenon Pharmaceuticals Inc. reports total compensation of $3,145,290 for Christopher Kenney in fiscal 2025, including a base salary of $565,000. Disclosed compensation is on record for 5 fiscal years. Christopher Kenney has spoken on 1 earnings call across 1 company, most recently for Xenon Pharmaceuticals Inc. on May 7, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Xenon Pharmaceuticals Inc. (XENE)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Xenon Pharmaceuticals Inc.
Other people whose current roles at this company are on record from its filings.
- Ian Mortimer CEO, Chief Accounting Officer, Board Member
- Simon Pimstone Chairman
- Thomas (Tucker) Kelly CFO
- Thomas Kelly CFO
- Tucker Kelly CFO
- Clarissa Desjardins Board Member
- Dawn Svoronos Board Member
- Dr. Clarissa Desjardins Board Member
- Dr. Gillian Cannon Board Member
- Elizabeth Garofalo Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Xenon Pharmaceuticals Inc. (XENE) | Chief Medical Officer | $565,000 | $3,145,290 |
| 2024 | Xenon Pharmaceuticals Inc. (XENE) | Chief Medical Officer | $540,000 | $4,196,940 |
| 2023 | Xenon Pharmaceuticals Inc. (XENE) | Chief Medical Officer | $510,000 | $3,578,066 |
| 2022 | Xenon Pharmaceuticals Inc. (XENE) | Chief Medical Officer | $465,000 | $3,263,857 |
| 2021 | Xenon Pharmaceuticals Inc. (XENE) | Chief Medical Officer | $162,115 | $1,935,409 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.